These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35575911)

  • 1. Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.
    de Lima VJT; da Silva AF; Kerbauy LN; Kerbauy MN; Lerner D; Colares M; Ribeiro AAF; da Silva CF; Hamerschlak N; Arcuri LJ
    Ann Hematol; 2022 Aug; 101(8):1795-1802. PubMed ID: 35575911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
    Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
    Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
    Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
    Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies.
    Alfaro Moya T; Salas MQ; Santos Carreira A; Atenafu EG; Law AD; Lam W; Pasic I; Kim DDH; Michelis FV; Novitzky Basso I; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Viswabandya A
    Bone Marrow Transplant; 2024 Apr; 59(4):534-540. PubMed ID: 38317015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
    Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
    Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
    Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
    Grunwald MR; Sha W; He J; Sanikommu S; Gerber JM; Ai J; Knight TG; Fasan O; Boseman V; Kaizen W; Chojecki A; Ragon BK; Symanowski J; Avalos B; Copelan E; Ghosh N
    Transplant Cell Ther; 2024 Dec; 30(12):1211.e1-1211.e11. PubMed ID: 39332808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
    Salas MQ; Pedraza A; Charry P; Suárez-Lledó M; Rodríguez-Lobato LG; Brusosa M; Solano MT; Serrahima A; Nomdedeu M; Cid J; Lozano M; Arcarons J; de Llobet N; Rosiñol L; Esteve J; Urbano-Ispizua Á; Carreras E; Fernández-Avilés F; Rovira M; Martinez C
    Transplant Cell Ther; 2024 Feb; 30(2):213.e1-213.e12. PubMed ID: 38042256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease after an outpatient peripheral blood hematopoietic cell transplant using reduced-intensity conditioning: a single-center LATAM experience.
    Jaime-Pérez JC; Meléndez-Flores JD; Valdespino-Valdes J; Gómez-De León A; Colunga-Pedraza PR; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D
    Expert Rev Hematol; 2024; 17(1-3):77-86. PubMed ID: 38226642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
    Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
    Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft.
    Little JS; Duléry R; Shapiro RM; Aleissa MM; Prockop SE; Koreth J; Ritz J; Antin JH; Cutler C; Nikiforow S; Romee R; Issa NC; Ho VT; Baden LR; Soiffer RJ; Gooptu M
    Transplant Cell Ther; 2024 Feb; 30(2):233.e1-233.e14. PubMed ID: 37984797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
    Inamoto Y; Flowers ME; Appelbaum FR; Carpenter PA; Deeg HJ; Furlong T; Kiem HP; Mielcarek M; Nash RA; Storb RF; Witherspoon RP; Storer BE; Martin PJ
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1088-92. PubMed ID: 21421070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
    Wieduwilt MJ; Metheny L; Zhang MJ; Wang HL; Estrada-Merly N; Marks DI; Al-Homsi AS; Muffly L; Chao N; Rizzieri D; Gale RP; Gadalla SM; Cairo M; Mussetti A; Gore S; Bhatt VR; Patel SS; Michelis FV; Inamoto Y; Badawy SM; Copelan E; Palmisiano N; Kharfan-Dabaja MA; Lazarus HM; Ganguly S; Bredeson C; Diaz Perez MA; Cassaday R; Savani BN; Ballen K; Martino R; Wirk B; Bacher U; Aljurf M; Bashey A; Murthy HS; Yared JA; Aldoss I; Farhadfar N; Liu H; Abdel-Azim H; Waller EK; Solh M; Seftel MD; van der Poel M; Grunwald MR; Liesveld JL; Kamble RT; McGuirk J; Munker R; Cahn JY; Lee JW; Freytes CO; Krem MM; Winestone LE; Gergis U; Nathan S; Olsson RF; Verdonck LF; Sharma A; Ringdén O; Friend BD; Cerny J; Choe H; Chhabra S; Nishihori T; Seo S; George B; Baxter-Lowe LA; Hildebrandt GC; de Lima M; Litzow M; Kebriaei P; Hourigan CS; Abid MB; Weisdorf DJ; Saber W
    Blood Adv; 2022 Jan; 6(1):339-357. PubMed ID: 34547770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?
    Mehta RS; Saliba RM; Hayase E; Jenq RR; Abraham S; Rashid A; Rondon G; Al-Atrash G; Bashir Q; Hosing CM; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Popat UR; Qazilbash MH; Ramdial J; Srour S; Champlin RE; Rezvani K; Shpall EJ; Alousi AM
    Transplant Cell Ther; 2022 Aug; 28(8):500.e1-500.e10. PubMed ID: 35662592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.